Xpert MTB/RIF Assay for Diagnosis of Tuberculous Meningitis (TBM) in Maharaj Nakorn Chiang Mai Hospital

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-01

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Early diagnosis and appropriate treatment of tuberculous meningitis (TBM) are crucial steps to reduce morbidity and mortality. The WHO recommended to use Xpert MTB/RIF assay to diagnose pulmonary TB, pediatrics TB, extra pulmonary TB and rifampicin resistance. However, the data of accuracy in diagnosis of TBM is still lacking. This study aimed to find out the diagnostic performance of Xpert MTB/RIF assay for the diagnosis of tuberculous meningitis, especially in patients who presented with subacute lymphocytic meningitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Xpert MTB/RIF Test in the Diagnosis of Pulmonary Tuberculosis

NCT04433195

Pulmonary Tuberculosis Confirmation by Culture

UNKNOWN NA

Sensitivity and Specificity of Xpert MTB/RIF Ultra

NCT06058065

Tuberculosis

UNKNOWN

Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects

NCT01587469

Tuberculosis

COMPLETED

Improve Treatment Outcomes for Tuberculosis Infection in Tertiary Care Hospitals

NCT03042754

Tuberculosis

ACTIVE_NOT_RECRUITING NA

Diagnosis of Tuberculous Meningitis by ESAT-6 in CSF

NCT01371916

Tuberculous Meningitis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tuberculous meningitis (TBM) was the most serious manifestation of Mycobacterium tuberculosis infection with high rates of morbidity and mortality if treatment is delayed, especially in HIV-infected patients. The fatality rates increased to 60 percent compared to about one third in non-HIV infection. Prevalence and incidence of TBM worldwide is unclear. In 2015, the incidences of TBM were approximately 6-10 percent. In Northern Thailand, from the national survey programs, the prevalence rates of TBM were about 9.7 per 100,000 people, and TBM was the most common cause of death in extra-pulmonary TB patients with mortality rates about 0.54 per 100,000 people. However, these may be underreported due to diagnostic problems.

Prompt and accurate diagnoses with early treatments, were the key elements to reduce deaths and disabilities in TBM. However, there were some major obstacles in the diagnostic procedures concerning the limitations, such as low sensitivity in conventional acid-fast bacilli (AFB) microscopy staining techniques or long turnaround times in gold-standard culture. Therefore, the delays in diagnoses lead to late managements and increased mortalities in TBM, especially in multidrug-resistance (MDR) cases. In the past, a lot of studies tried to solve these problems urgently, but the low frequency of confirmed cases and the absence of a consensus clinical case definition were the huge barriers causing a lack of progression in new clinical trials. In 2010, a uniform clinical case definition for use in clinical research about TBM was established. They used criteria from clinical characteristics, cerebrospinal fluid (CSF) examinations, neuroimaging studies, and evidence of tuberculosis elsewhere. Additionally, microbiological or pathological proof was used to classify the patients who had signs and symptoms of meningitis and were defined as definite, probable, possible, and not tuberculous meningitis. Since then, many clinical studies about TBM diagnosis were developed and made more convenient.

The Xpert MTB/RIF assay was the closed-cartridge-based system heminested PCR for the diagnosis of tuberculosis (TB), and detecting the rifampicin resistant gene in sputum and the CSF. This can be used as a marker for MDR-TB, focused on endemic areas and HIV coinfection. This test has better diagnostic threshold levels (80-100 cfu/ml) than the 5,000 cfu/ml in AFB microscopy staining techniques, shorter duration for the results than conventional TB cultures, and more simplification than nucleic-acid amplification tests. Many studies about the diagnostic accuracy revealed that sensitivity and specificity of this new test varied from 50-86 % and 94-98 % depended on method, population, and laboratory techniques. There were some discussions about the application practicality in the diagnosis of TBM, such as in a large-population study in Vietnam that questioned the lower sensitivity and cost-effectiveness compared with conventional staining and culture. Subsequently, this newer rapid test was approved by WHO for TBM diagnosis.

In Thailand, one of the countries with a high burden of tuberculosis, despite many advantages, use of this test was limited in CSF specimens due to the lack of data, including accuracy in CSF specimens for TBM diagnosis among the Thai population. This study aims to prospectively find out the diagnostic performance and accuracy of Xpert MTB/RIF in CSF samples from patients who presented with subacute lymphocytic meningitis in Northern Thailand, which can be the database for extending the study to cover patients in other parts of Thailand.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculous Meningitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

All patients older than 15 years old with subacute lymphocytic meningitis presenting to the internal medicine clinics of Maharaj Nakorn Chiang Mai hospital between January 2015 and March 2016 were recruited for the study.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Xpert

Centrifuged CSF sent for Xpert MTB/RIF

Group Type EXPERIMENTAL

Xpert MTB/RIF

Intervention Type DIAGNOSTIC_TEST

CSF samples was centrifuged at 3,000 - 4,000 X g for 15 minutes. Supernatant was removed to leave a 1-ml precipitate, which was then used for Ziehl-Neelsen AFB staining (100 μl), inoculation of MGIT culture (100 μl), and Xpert MTB/RIF testing (800 μl).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xpert MTB/RIF

CSF samples was centrifuged at 3,000 - 4,000 X g for 15 minutes. Supernatant was removed to leave a 1-ml precipitate, which was then used for Ziehl-Neelsen AFB staining (100 μl), inoculation of MGIT culture (100 μl), and Xpert MTB/RIF testing (800 μl).

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Presence of meningitis symptoms and signs including one or more of the following: headache, irritability, vomiting, fever, neck stiff ness, convulsions, focal neurological deficits, altered consciousness, or lethargy at least 5 days prior to admission, plus
2. CSF with abnormalities of at least two of these three characters;

* Lymphocytic pleocytosis (≥ 50%)
* More than 40 mg/ml of protein
* Lower than 0.5 of CSF: blood sugar ratio